Clinical Trial Update: Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 study of ibrutinib followed by ibrutinib in combination with nivolumab in non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• OPDIVO (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer, Nonsmall Cell, Stage I | Phase 2 | Status: WITHDRAWN